From discovery to development

An innovative portfolio for drug development

NGS for Drug Development

Illumina provides an innovative portfolio of genomic sequencing systems, products, and services for the drug development pipeline. With solutions to inform the drug development process, you can confidently choose us as a partner from discovery through companion diagnostics development.

We are uniquely positioned to deliver products and services to support pharmaceutical development with the largest install base of next-generation sequencing (NGS) instrumentation.

Approximately 90 percent of all sequencing data produced today has been generated using Illumina technologies*. Reference and service labs are installing our instruments in increasing numbers to perform a wide variety of applications.

* Data calculations on file. Illumina, Inc. 2017

The Illumina portfolio of solutions informs various stages of the drug development process.

Click on the below to view methods and products supporting drug development.

Whole-Genome Sequencing

Take a comprehensive view of the genomic variation linked to a pathway.

Whole-Exome Sequencing

Explore genomic variation in a more cost-effective way.

Targeted Cancer Sequencing

Take a deeper view to confirm genomic variation of interest with custom or fixed panels. Detect single-nucleotide variants (SNVs), amplifications, and fusions that contribute to solid tumor progression with TruSight Tumor 170.

Cancer RNA Sequencing

Characterize expression by sequencing individual targets to the entire transcriptome.

Cancer Immunotherapy Research

NGS methods enable efficient, broad, and deep assessment of tumors and their microenvironment.

Drug Response RNA Biomarker Discovery

Learn how to use RNA-Seq to identify novel RNA-based drug response biomarkers.

Sequencing Systems

Find the sequencer that best fits your scale of study.

Microarray Solutions

A complete range of tools and services for every need.

Bioinformatics Tools

Informatics tools to guide you from experimental design to data interpretation and reporting.

Service Providers

Find a service provider through our Propel program to support your genomics needs.

Targeted Cancer Sequencing

Take a deeper view to confirm genomic variation of interest with custom or fixed panels. Detect single-nucleotide variants (SNVs), amplifications, and fusions that contribute to solid tumor progression with TruSight Tumor 170.

Cancer RNA Sequencing

Confirm expression in transcripts of interest with targeted panels and access hard-to-analyze FFPE samples. Also leverage RNA-Seq for the discovery and profiling of RNA-based drug response biomarkers.

Immunotherapy Research

NGS methods enable efficient, broad, and deep assessment of tumors and their microenvironment

Sequencing Systems

Find the sequencer that best fits your scale of study.

Informatics

Bioinformatics tools guide you from experimental design to data interpretation and reporting.

Service Providers

Find a service provider through our Propel program to support your genomics needs.

Targeted Cancer Sequencing

Take a deeper view to confirm genomic variation of interest with custom or fixed panels. Detect single-nucleotide variants (SNVs), amplifications, and fusions that contribute to solid tumor progression with TruSight Tumor 170.

Cancer RNA Sequencing

Confirm expression in transcripts of interest with targeted panels and access hard-to-analyze FFPE samples. Also leverage RNA-Seq to discover and profile drug response RNA biomarkers.

Immunotherapy Research

NGS methods enable efficient, broad, and deep assessment of tumors and their microenvironment

Sequencing Systems

Find the sequencer that best fits your scale of study.

Informatics

Bioinformatics tools guide you from experimental design to data interpretation and reporting.

Service Providers

Find a service provider through our Propel program to support your genomics needs.

Explore our unique, multi-analyte approach to co-development.

Targeted Cancer Sequencing

Take a deeper view to confirm genomic variation of interest with custom or fixed panels. Detect single-nucleotide variants (SNVs), amplifications, and fusions that contribute to solid tumor progression with TruSight Tumor 170.

Cancer RNA Sequencing

Confirm expression in transcripts of interest with targeted panels and access hard-to-analyze FFPE samples.

Immunotherapy Research

NGS methods enable efficient, broad, and deep assessment of tumors and their microenvironment.

Sequencing Systems

Find the sequencer that best fits your scale of study.

Companion Diagnostic Development

Explore our unique, multi-analyte approach to co-development.

High-Throughput Genotyping Research Tools

Gain meaningful insights from complex populations.

Informatics

Bioinformatics tools guide you from experimental design to data interpretation and reporting.

Service Providers

Find a service provider through our Propel program to support your genomics needs.

Companion Diagnostic Development

Explore our unique, multi-analyte approach to co-development.

MiSeqDx Instrument

Discover the first FDA-cleared next-generation sequencing system.

NextSeq550Dx Instrument

Explore the next level in diagnostic power for the clinical lab.

High-Throughput Genotyping Research Tools

Gain meaningful insights from complex populations.

Service Providers

Find a service provider through our Propel program to support your genomics needs.

Interested in receiving newsletters, case studies, and information on genomics in drug development? Enter your email address.
Service Partners and Programs
Service Partners and Programs

The Propel Certification Program is designed to promote high data quality and best practices at fee-for-service labs powered by Illumina.

Learn More